Pegasus Partners Ltd. Bristol Myers Squibb CO Transaction History

Pegasus Partners Ltd.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 10, 2022	SELL	$0.13 - $76.84 $39 - $23,205	-302 Reduced 8.27%	3,350 $238,000
Q2 2022 Aug 12, 2022	SELL	$72.62 - $79.98 $7,116 - $7,838	-98 Reduced 2.61%	3,652 $281,000
Q1 2022 May 13, 2022	BUY	$61.48 - $73.72 $230,550 - $276,450	3,750 New	3,750 $274,000
Q3 2021 Nov 12, 2021	SELL	$59.17 - $69.31 $192,302 - $225,257	-3,250 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$57.74 - $65.43 $187,655 - $212,647	3,250 New	3,250 $202,000
Q1 2020 May 11, 2020	SELL	$46.4 - $67.43 $363,126 - $527,707	-7,826 Closed	0 $0
Q4 2019 Feb 12, 2020	BUY	$49.21 - $64.19 $385,117 - $502,350	7,826 New	7,826 $502,000
Q4 2018 Feb 01, 2019	SELL	$48.76 - $63.23 $193,674 - $251,149	-3,972 Closed	0 $0
Q2 2018 Jul 27, 2018	SELL	$50.53 - $62.98 $25,517 - $31,804	-505 Reduced 11.28%	3,972 $220,000
Q1 2018 May 09, 2018	BUY	$59.92 - $68.98 $10,306 - $11,864	172 Added 4.0%	4,477 $283,000
Q3 2017 Nov 09, 2017	BUY	$55.23 - $63.74 $237,765 - $274,400	4,305	4,305 $274,000

2,533

1.47B

31.6M

35M

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $124B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

Get notified when there are updates to the investment portfolio of Pegasus Partners Ltd., based on Form 13F filings with the SEC.

Stay updated on Pegasus Partners Ltd. with notifications on news.